EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

Growth Factors

Volumn 30, Issue 2, 2012, Pages 107-116

  Wilson, Kristy J ^a,b   Mill, Christopher ^a,c   Lambert, Sydney ^a   Buchman, Jennifer ^a   Wilson, Timothy R ^d,e   Hernandez Gordillo, Victor ^a   Gallo, Richard M ^a   Ades, Laura M C ^a   Settleman, Jeffrey ^d,e   Riese II, David J ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUBURN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e GENENTECH INC   (United States)

Author keywords

Amphiregulin; autocrine and paracrine growth regulation; EGF; EGF receptor; ligand specificity; TGF

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; AMPHIREGULIN; BETACELLULIN; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGEN; EPIREGULIN; GROWTH FACTOR; NEUREGULIN 2 BETA; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; BREAST CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; MUTATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; MICE; PARACRINE COMMUNICATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE;

EID: 84858975825     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.649918     Document Type: Article

References (34)

1. Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JR, Jr, Luttrell LM, Raymond JR, Sr. 2009. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry 48:1462-1473.
2. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257. (Pubitemid 26075021)
3. Citri A, Yarden Y. 2006. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516. (Pubitemid 44036456)
4. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H. 2003. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278:28950-28960. (Pubitemid 36935806)
5. Eden ER, Huang F, Sorkin A, Futter CE. 2011. The role of EGF receptor ubiquitination in regulating its intracellular traffic. Traffic, in press. DOI: 10.1111/j.1600-0854.2011.01305.x. [Epub ahead of print]
6. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ, 2nd. 2010. EGFR signaling in breast cancer: Bad to the bone. Semin Cell Dev Biol 21:951-960.
7. Gilmore JL, Gallo RM, Riese DJ. 2006. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J 396:79-88. (Pubitemid 43764499)
8. Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ, 2nd, Foley J. 2008. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 110:493-505. (Pubitemid 351962595)
9. Grovdal LM, Stang E, Sorkin A, Madshus IH. 2004. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300:388-395. (Pubitemid 39314428)
10. Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ, 2nd. 2004. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23: 883-893. (Pubitemid 38250933)
11. Johnson GR, Kannan B, Shoyab M, Stromberg K. 1993. Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells. J Biol Chem 268:2924-2931. (Pubitemid 23057930)
12. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. 2007. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 120:3688-3699. (Pubitemid 350120960)
13. Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. 2007. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer 96:1569-1578.
14. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029-1040. (Pubitemid 30054908)
15. Mill CP, Gettinger KL, Riese DJ, 2nd. 2011. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317:392-404.
16. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18:3587-3596.
17. Penington DJ, Bryant I, Riese DJ, 2nd. 2002. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 13:247-256. (Pubitemid 34755377)
18. Ravid T, Heidinger JM, Gee P, Khan EM, Goldkorn T. 2004. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem 279: 37153-37162. (Pubitemid 39129066)
19. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. 2008. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19:73-80.
20. Riese DJ, 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF. 1995. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15:5770-5776.
21. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, Willumsen BM, van Deurs B. 2009. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10:1115-1127.
22. Rotin D, Margolis B, Mohammadi M, Daly RJ, Daum G, Li N, Fischer EH, Burgess WH, Ullrich A, Schlessinger J. 1992. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: Identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. Embo J 11: 559-567.
23. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. 1989. Structure and function of human amphiregulin: A member of the epidermal growth factor family. Science 243:1074-1076. (Pubitemid 19072586)
24. Sorkin A, Goh LK. 2009. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315:683-696.
25. Stern KA, Place TL, Lill NL. 2008. EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J 410:585-594. (Pubitemid 351429029)
26. Suh PG, Park JI, Manzoli L, Cocco L, Peak JC, Katan M, Fukami K, Kataoka T, Yun S, Ryu SH. 2008. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 41:415-434. (Pubitemid 351914885)
27. VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ, 2nd. 2005. Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem 48:7445-7456. (Pubitemid 41743658)
28. van de Poll ML, van RotterdamW, Gadellaa MM, Jacobs-Oomen S, van Zoelen EJ. 2005. Ligand depletion negatively controls the mitogenic activity of epidermal growth factor. Exp Cell Res 304:630-641. (Pubitemid 40321138)
29. Walker-Daniels J, Riese DJ, 2nd, Kinch MS. 2002. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 1:79-87. (Pubitemid 36330213)
30. Willmarth NE, Ethier SP. 2006. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 281:37728-37737. (Pubitemid 46042076)
31. Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ, 2nd, Ethier SP. 2009. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 21:212-219.
32. Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ, 2nd. 2007. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun 364: 351-357. (Pubitemid 350011072)
33. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ, 2nd. 2009. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol Ther 122:1-8.
34. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Janne PA. 2008. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14: 6963-6973.